207 related articles for article (PubMed ID: 11517236)
1. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity.
van der Stelt M; Veldhuis WB; Bär PR; Veldink GA; Vliegenthart JF; Nicolay K
J Neurosci; 2001 Sep; 21(17):6475-9. PubMed ID: 11517236
[TBL] [Abstract][Full Text] [Related]
2. Exogenous anandamide protects rat brain against acute neuronal injury in vivo.
van der Stelt M; Veldhuis WB; van Haaften GW; Fezza F; Bisogno T; Bar PR; Veldink GA; Vliegenthart JF; Di Marzo V; Nicolay K
J Neurosci; 2001 Nov; 21(22):8765-71. PubMed ID: 11698588
[TBL] [Abstract][Full Text] [Related]
3. In vivo excitotoxicity induced by ouabain, a Na+/K+-ATPase inhibitor.
Veldhuis WB; van der Stelt M; Delmas F; Gillet B; Veldink GA; Vliegenthart JF; Nicolay K; Bär PR
J Cereb Blood Flow Metab; 2003 Jan; 23(1):62-74. PubMed ID: 12500092
[TBL] [Abstract][Full Text] [Related]
4. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
[TBL] [Abstract][Full Text] [Related]
5. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.
Romero J; Garcia-Palomero E; Castro JG; Garcia-Gil L; Ramos JA; Fernandez-Ruiz JJ
Brain Res Mol Brain Res; 1997 Jun; 46(1-2):100-8. PubMed ID: 9191083
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat.
Freedland CS; Whitlow CT; Miller MD; Porrino LJ
Synapse; 2002 Aug; 45(2):134-42. PubMed ID: 12112406
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases.
Veldhuis WB; van der Stelt M; Wadman MW; van Zadelhoff G; Maccarrone M; Fezza F; Veldink GA; Vliegenthart JF; Bär PR; Nicolay K; Di Marzo V
J Neurosci; 2003 May; 23(10):4127-33. PubMed ID: 12764100
[TBL] [Abstract][Full Text] [Related]
8. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.
Petitet F; Jeantaud B; Reibaud M; Imperato A; Dubroeucq MC
Life Sci; 1998; 63(1):PL1-6. PubMed ID: 9667767
[TBL] [Abstract][Full Text] [Related]
9. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
Oviedo A; Glowa J; Herkenham M
Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
[TBL] [Abstract][Full Text] [Related]
10. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity.
Katsidoni V; Kastellakis A; Panagis G
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2273-84. PubMed ID: 23830148
[TBL] [Abstract][Full Text] [Related]
11. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
Darmani NA
Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
[TBL] [Abstract][Full Text] [Related]
12. Delta9-tetrahydrocannabinol (Delta9-THC) prevents cerebral infarction via hypothalamic-independent hypothermia.
Hayakawa K; Mishima K; Nozako M; Hazekawa M; Ogata A; Fujioka M; Harada K; Mishima S; Orito K; Egashira N; Iwasaki K; Fujiwara M
Life Sci; 2007 Mar; 80(16):1466-71. PubMed ID: 17289082
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol.
García-Gil L; Romero J; Ramos JA; Fernández-Ruiz JJ
Drug Alcohol Depend; 1999 Jun; 55(1-2):127-36. PubMed ID: 10402157
[TBL] [Abstract][Full Text] [Related]
14. Δ9-tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity.
Castelli MP; Madeddu C; Casti A; Casu A; Casti P; Scherma M; Fattore L; Fadda P; Ennas MG
PLoS One; 2014; 9(5):e98079. PubMed ID: 24844285
[TBL] [Abstract][Full Text] [Related]
15. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
Fernández-Ruiz JJ; Muñoz RM; Romero J; Villanua MA; Makriyannis A; Ramos JA
Biochem Pharmacol; 1997 Jun; 53(12):1919-27. PubMed ID: 9256167
[TBL] [Abstract][Full Text] [Related]
16. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.
Lastres-Becker I; Bizat N; Boyer F; Hantraye P; Brouillet E; Fernández-Ruiz J
Neuroreport; 2003 May; 14(6):813-6. PubMed ID: 12858038
[TBL] [Abstract][Full Text] [Related]
17. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
[TBL] [Abstract][Full Text] [Related]
18. Chronic exposure to delta 9-tetrahydrocannabinol fails to irreversibly alter brain cannabinoid receptors.
Westlake TM; Howlett AC; Ali SF; Paule MG; Scallet AC; Slikker W
Brain Res; 1991 Mar; 544(1):145-9. PubMed ID: 1649662
[TBL] [Abstract][Full Text] [Related]
19. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors.
Breivogel CS; Scates SM; Beletskaya IO; Lowery OB; Aceto MD; Martin BR
Eur J Pharmacol; 2003 Jan; 459(2-3):139-50. PubMed ID: 12524139
[TBL] [Abstract][Full Text] [Related]
20. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells.
Sánchez C; Galve-Roperh I; Canova C; Brachet P; Guzmán M
FEBS Lett; 1998 Sep; 436(1):6-10. PubMed ID: 9771884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
